Alzheimer’s disease (AD) is the most common cause of dementia and affects nearly 5.9 million adults in the United States. Agitation is a highly prevalent behavioral neuropsychiatric symptom associated with dementia and represents a leading cause for institutionalization.
The current diagnostic criteria for AD and other dementias often focus on related cognitive deficits, but the behavioral neuropsychiatric symptoms can be the most troublesome and lead to poor quality of life.
Agitation associated with dementia represents a leading cause for institutionalization.
There are no FDA-approved treatments for the behavioral neuropsychiatric symptoms, including agitation and aggression. Therefore, physicians often resort to off-label use of antipsychotic medications which are associated with serios adverse events. There is a large unmet medical need for safe and effective therapies to treat the behavioral symptoms in patients with AD and other dementias.